LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT OF THE COMPANY

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with information on the latest product development of the Company.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 8 June 2017, the Company received a written notice from China Food and Drug Administration (the "**CFDA**") stating that our LAmbre™ left atrial appendage ("**LAA**") occluder system ("**LAmbre™ LAA occluder**") has been granted with a CFDA certificate in China.

LAmbre™ LAA occluder became the only LAA closure product from a Chinese brand to obtain such certification. This not only marked the entrance of the Company's innovative and cutting-edge LAA closure product into the Chinese market, but also represented the end of the monopoly of such foreign products in the Chinese market, which will bring benefit to vast numbers of domestic patients. Furthermore, it marks the leap of the Company's business from congenital heart diseases products to structural heart diseases products.

The Company began its research on the LAA occluder system since 2003 and officially commenced the research and development of the LAA closure product in 2010. The main design of the LAmbre™ LAA occluder consists of a distal umbrella and a proximal cover disc connected by a short sleeve, and is designed for left atrial appendage closure via percutaneous transcatheter procedure, which is used to treat patients with non-valvular atrial fibrillation who has high risk of stroke and contraindicated to oral anticoagulants for a long time or those who has risk of stroke even with anticoagulation therapy, to prevent stroke caused by thrombus

embolization from the LAA. In addition, the occluder design would allow the device to adapt to various LAA anatomies and sizes, fully re-capture and re-position during the whole procedure, and be delivered with small sheath. These characteristics make the LAmbre™ LAA occluder system safe and easy to use with a short learning curve for physicians. Through clinical trials, the LAmbre™ LAA occluder system has received much praise and was highly regarded by doctors and patients globally. It is expected that the LAmbre™ LAA occluder system will occupy the mainstream markets of China, Europe and other regions.

Since obtaining the CE certificate in 2016, our LAA closure product was successfully launched in overseas market. Currently, obtaining the CFDA certification is expected to further assist the Company to expand its market share, enhance competitiveness and market position in Chinese market, thereby strongly promoting the steady development of the Group.

Going forward, the Company reaffirms its commitment in independent innovation and development, in pursuit of benefitting patients globally through its minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders.

By Order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and
Chief Executive Officer

Hong Kong, 8 June 2017

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong and Ms. XIAO Ying being executive Directors; Mr. MONAGHAN Shawn Del, Mr. JIANG Feng and Mr. CLEARY Christopher Michael being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.